Clinical Trial: Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury

U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT07518303) titled 'Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury' on March 29.

Brief Summary: Sepsis-associated acute kidney injury (SA-AKI) is common in critically ill patients and often requires continuous kidney replacement therapy (CRRT). The choice of blood thinner (anticoagulation) during CRRT affects how long the filter works and the risk of bleeding. Citrate is the current standard blood thinner, but it can cause metabolic problems in patients with shock or liver dysfunction. Nafamostat mesylate (NM) is a newer alternative with a very short half-lif...